Clinical trials for aortic valve disease 1 are likely to be worthwhile, particularly in patients older than 65 years who have experienced an MI and/or symptomatic disease at a high-risk position of the aortic root.
Data from a recent study confirms that people using the Medtronic TAVRs are not at an increased risk of life-threatening procedural complications either in the short- or the long term.
There have not been any new discoveries for treating AV disease 1, but treatments and surgical options are available to address the needs of patients with AV disease 1.
Aortic valve disease 1 is a disorder characterized by the remodeling of the aortic valve that progressively leads to heart failure and eventually death. Findings from a recent study provide evidence that the calcification of the aortic valve appears to be initiated by abnormal matrix turnover and tissue remodeling and that calcification progresses within an existing atherosclerotic aortic stenosis. Thus, our study sheds further mechanistic insights into its etiology.
Patients with aortic valve stenosis (AVS) have symptoms of heart failure such as fatigue, shortness of breath, cough and chest discomfort and dizziness. Patients with severe stenosis may present with symptoms of breathlessness (dyspnoea) and fainting as well as orthopnea or paroxysms if there is aortic regurgitation (severe regurgitation causes symptoms of chest pain or a murmur).\n
Data from a recent study of this study suggest that the majority of people cannot be cured of aortic valve disease 1. However, people do well.
Nearly 2 million people in the United States receive AVD within the first year of life, and about 30,000 people annually die of AVD. Most cases of AVD in the US are attributable to rheumatic diseases, such as SLE. This was the first study to analyze AVD-related mortality in the large US population. Results from a recent clinical trial suggest that AVD is a major health issue in the US and should be treated.
Findings such as increased jugular venous pressure, elevated jugular bulb, and elevated jugular venous refill time in patients with severe aortic stenosis demonstrate the presence of a dynamic component of aortic insufficiency. Furthermore, findings such as dilated left ventricle to a pulsed pressure gradient (>20 mm Hg) indicates the presence of severe aortic stenosis. This same information is also useful in cases of a patient with a high-output left ventricular assist system who is being positioned for hemodialysis or peritoneal dialysis.
Aortic valve replacement is a common treatment for severe aortic stenosis. This procedure involves the implantation of heart valve prosthetic implants. A procedure to restore the aortic valve function may be considered to prevent sudden cardiac death. In cases with aortic regurgitation, this procedure may be required.
Most patients will feel comfortable after the procedure. However the patient should always be reminded that the procedure will take 15 minutes. Some doctors and medical centers may have a waiting list, in which case you should consult a cardiologist soon after your procedure in order to prevent complications. Patients should use their own wrist scale to make sure they still feel comfortable. If you have any questions contact your doctor immediately. Follow up is on an as needed basis. If you need to replace your stent you can do so on a regular basis at your medical provider's office or through your patient support program.
The Medtronic bioprosthesis, which was already approved in Europe for aortic valve stenosis, can be implanted in a subset of patients with aortic insufficiency without the need for aortic root replacement.
Although there is no evidence to support the application of these results to the general population of patients undergoing transcatheter aortic valve implantation, the experience reported herein could serve as a guide for surgeons and patients considering the use of the Medtronic CoreValve.